You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
The U.S. Food and Drug Administration is worried that clinical researchers might ask safety officials to approve studies involving human subjects that have been rejected by other panels. To deter "IRB shopping," the government has proposed that researchers be required to tell safety panels about any prior reviews. But last week the biomedical community gave the plan a mixed reception.
